Ozi ndị ọzọ ― Igbo

Confluent and reticulated papillomatosis (CRP) , nke a na-akpọkwa ọrịa Gougerot-Carteaud, na-esite na uto mkpụrụ ndụ akpụkpọ ahụ na-adịghị mma. Ọ na-egosi dị ka ntụpọ gbara ọchịchịrị na-enweghị mgbu nke nwere ike ịbanye n'ime patches buru ibu, na-apụtakarị n'elu obi na olu nke ndị nọ n'afọ iri na ụma na ndị na-eto eto. Nhọrọ ọgwụgwọ mbụ bụ minocycline.
Confluent and reticulated papillomatosis (CRP), also known as Gougerot-Carteaud syndrome, is caused by disordered keratinization. It presents with asymptomatic hyperpigmented papules that can coalesce into plaques and are typically located on the upper trunk and neck of teens and young adults. First-line treatment is oral 'minocycline'.

CRP na-apụtakarị dị ka ntụpọ gbara ọchịchịrị na patches na-enweghị ihe mgbaàmà n'akpụkpọ ahụ n'olu, ogwe aka, obi elu, na azụ elu. Mgbe ụfọdụ, ọ nwere ike gbasaa ruo n'egedege ihu yana gbadaa n'akụkụ ọnụ. Ọgwụ nje dị ka minocycline aghọọla nhọrọ ọgwụgwọ kacha amasị.
CRP typically presents as asymptomatic hyperpigmented papules and plaques with peripheral reticulation over the nape, axillae, upper chest, and upper back, occasionally with extension superior to the forehead and inferior to the pubic region. Antibiotics, such as 'minocycline', at anti-inflammatory doses have emerged as a preferred therapeutic option.